NeueHealth Expects FY24 Enterprise Revenue Of $1B; Enterprise Adjusted EBITDA Of $15M - $25M
$NEUE
Medical Specialities
Health Care
NeueHealth Expects FY24 Enterprise Revenue Of $1B; Enterprise Adjusted EBITDA Of $15M - $25M
Save time and jump to the most important pieces.
NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today announced that Centrum Health, one of the Company's value-driven clinic brands, became a wholly owned subsidiary through the Company's acquisition of the remaining 25% equity interest of the business that it did not already own. This action simplifies NeueHealth's corporate structure, streamlining operations to support its ongoing focus on advancing its value-driven, consumer-centric care model. "We are pleased to announce this transaction as it further positions NeueHealth to take the lead in creating a more coordinated, seamless healthcare experience for all consumers," said Mike Mika
NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Thursday, November 7, 2024, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests partic
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model and delivering high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2024. "We continued to build momentum
NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today announced that Centrum Health, one of the Company's value-driven clinic brands, became a wholly owned subsidiary through the Company's acquisition of the remaining 25% equity interest of the business that it did not already own. This action simplifies NeueHealth's corporate structure, streamlining operations to support its ongoing focus on advancing its value-driven, consumer-centric care model. "We are pleased to announce this transaction as it further positions NeueHealth to take the lead in creating a more coordinated, seamless healthcare experience for all consumers," said Mike Mika
NeueHealth, Inc. ("NeueHealth") (NYSE:NEUE), the value-driven healthcare company, today announced it will report Third Quarter financial results before the financial markets open on Thursday, November 7, 2024, followed by a conference call at 8:00 AM Eastern Time. To participate via telephone, please pre-register at this link. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including dial-in number, conference number, and personal code that can be used to access the call. A webcast of the earnings call may also be accessed via NeueHealth's Investor Relations page at investors.neuehealth.com. The company suggests partic
Drove solid Q2 ‘24 results with continued focus on advancing value-driven model and delivering high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2024. "We continued to build momentum
8-K - NeueHealth, Inc. (0001671284) (Filer)
8-K - NeueHealth, Inc. (0001671284) (Filer)
8-K - NeueHealth, Inc. (0001671284) (Filer)
4 - NeueHealth, Inc. (0001671284) (Issuer)
4 - NeueHealth, Inc. (0001671284) (Issuer)
4 - NeueHealth, Inc. (0001671284) (Issuer)
SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)